Literature DB >> 2106398

False-positive ketone tests: a bedside measure of urinary mesna.

M P Goren1, C B Pratt.   

Abstract

The sulfhydryl mesna is increasingly used to protect the bladder and kidney from effects of chemotherapy with ifosfamide and cyclophosphamide. Mesna reacts with reagents on urinary test strips designed to detect ketones. Test-strip results were correlated to sulfhydryl concentrations in 931 urine specimens obtained after infusions of mesna. These data may be used to estimate urinary mesna concentrations at the bedside or to test compliance in outpatients given oral mesna therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106398     DOI: 10.1007/bf00686240

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  False-positive ketonuria during ifosfamide and mesna therapy.

Authors:  B M Cantwell; J Pooley; A L Harris
Journal:  Eur J Cancer Clin Oncol       Date:  1986-02

2.  Ifosfamide/mesna and hematuria.

Authors:  C B Pratt; M P Goren
Journal:  Cancer Treat Rep       Date:  1987-11

Review 3.  Mesna--a short review.

Authors:  I C Shaw; M I Graham
Journal:  Cancer Treat Rev       Date:  1987-06       Impact factor: 12.111

4.  Mesna and false-positive results in ward testing for urinary ketones.

Authors:  E C Gordon-Smith; J M Hows; L Ward; K Woods; J I Dalton
Journal:  Lancet       Date:  1982-03-06       Impact factor: 79.321

5.  False positive reaction for urinary ketones with mesna.

Authors:  A Ben Yehuda; A Heyman; D Steiner-Salz
Journal:  Drug Intell Clin Pharm       Date:  1987-06

6.  False-positive results for ketone with the drug mesna and other free-sulfhydryl compounds.

Authors:  G Csako
Journal:  Clin Chem       Date:  1987-02       Impact factor: 8.327

7.  The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.

Authors:  G L Andriole; J T Sandlund; J S Miser; V Arasi; M Linehan; I T Magrath
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

Review 8.  Ifosfamide.

Authors:  M Zalupski; L H Baker
Journal:  J Natl Cancer Inst       Date:  1988-06-15       Impact factor: 13.506

9.  Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.

Authors:  M S Jones; R D Murrell; I C Shaw
Journal:  Eur J Cancer Clin Oncol       Date:  1985-05

10.  Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.

Authors:  C B Pratt; E C Douglass; E Etcubanas; M P Goren; A A Green; F A Hayes; M E Horowitz; W H Meyer; E I Thompson; J A Wilimas
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.